

INVESTOR PRESENTATION

MAY 2019





FORWARD LOOKING STATEMENTS

Safe Harbor Statement

This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "hopes," "intends," "estimates," "expects," "projects," "plans," "look forward to," "anticipates" and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. These forward-looking statements are not guarantees of performance and actual results could differ materially from those contained in such statements. These forward-looking statements are based on our current expectations and beliefs concerning future events affecting us and involve known and unknown risks and uncertainties that may cause our actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties are discussed in greater detail in our Annual Report on Form 10-K and Quarterly Report on Form 10-Q under the caption "Risk Factors" and in other documents filed by us from time to time with the Securities and Exchange Commission. We caution you not to place undue reliance on the forward-looking statements contained in this presentation. All forward-looking statements are based on information currently available to us as of today, and we undertake no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.

Health Claims Disclaimer

Statements made in this presentation and appendices have not been evaluated by the Food and Drug Administration. LifeVantage products are not intended to treat, cure, prevent or mitigate any disease. The statements in this presentation are for investors' educational purposes only.



THE COMPANY: LifeVantage (NASDAQ: LFVN)

We believe the secret to unlocking your potential is found in your DNA. LifeVantage is dedicated to helping you master it.

We are a pioneer in Nutrigenomics - a new science dedicated to cracking the human aging code.

We agree with leading researchers that extending human life is inevitable, and we have already made strides to achieve it. However, we believe that in order to truly enjoy extreme longevity, we need to biohack both our physical and financial health. That is why we have combined our pioneering nutrigenomics efforts with a subscription-based entrepreneurial vehicle.

Our products are sold exclusively through that entrepreneurial vehicle - our network of independent distributors.





NASDAQ Ticker	LFVN	Share price ¹	\$11.12
Shares outstanding ¹	14.3 million	Float ¹	13.2 million
Market Capitalization ¹	\$159.5 million	Enterprise Value ¹	\$145.5 million
Average Daily Volume ¹	131,177	Fiscal 2018 Revenue	\$203.2 million
Cash at March 31, 2019	\$15.9 million	Fiscal 2018 Adjusted EBITDA ²	\$14.9 million
Debt at March 31, 2019	\$1.9 million	Fiscal 2018 Adjusted EPS ²	\$0.51

INDUSTRY TRENDS

MAY 2019



TRENDS

THE RISE OF THE HEALTH ACTIVATED INDIVIDUAL

- Rapid democratization of genomic and other personalized health data is giving rise to a new wave of health-conscious individuals
- More than ever, education and understanding of one's own health is becoming widespread
- Individuals will research, measure and manage their overall health much like their personal finances
- Millennials have become a major driving force, empowered by ready access to genomic testing, health tools and a social network environment filled with influencers, all with a desire to hack the code to a healthier lifestyle

Biohacking

LifeVantage is a biohacking company.

Using nutrigenomics to optimize the human body for increased health.

- These trends have led to the emergence of "Biohacking"
 - The art of hacking your biology using nature's built-in mechanisms to stack the cards in your favor and become the best version of yourself
 - Bio-hacking is using science and personalized results to take control of and upgrade your body, your mind and your life
- Our mission is to "Biohack the Aging Code" through the relentless pursuit of science-based, nutrigenomic products with the intent of helping our customers live longer, healthier lives



BIOHACKING PRODUCTS

PATENTED

Several patents, including our initial patent "Compositions And Methods For Alleviating Inflammation And Oxidative Stress In A Mammal"

SCIENCE-BACKED

Protandim Studies conducted at the following institutions:

The Ohio State University

LSU

University of Colorado Denver Colorado State University

Virginia Commonwealth University

Texas Tech University

PEER-REVIEWED PUBLISHED RESEARCH

Research published in the following medical journals:

Free Radical Biology & Medicine

Enzyme Research

Circulation

American Journal of Physiology—Lung Cellular and Molecular Physiology



LifeVantage. PROTANDIM® * NRF2 SYNERGIZER®



LifeVantage.

PROTANDIM®



BACKED BY 27 CLINICAL STUDIES AND COUNTING. INCLUDING:

In a study conducted by the National Institute of Aging and published in the journal "Aging Cell", Protandim Nrf2 Synergizer was

"proven to significantly increase the lifespan of male mice, with a 7% increase in median survival. This is the only nutritional supplement tested that has been proven to increase the median survival in mice, thus delaying the aging process."

In a human clinical study published in "Free Radical Biology and Medicine", vol 40, issue 2, Protandim Nrf2 Synergizer was also proven to reduce oxidative stress by an average of 40% in only 30 days.

INDUSTRY TRENDS

NUTRIGENOMICS

NU·TRI·GE·NO·MICS/ˌn(y)ootrije nomiks,

The scientific study of the interaction of nutrition and human genes. Especially with regard to the prevention or treatment of disease.

"The Nutrigenomics market is expected to reach

\$17,313,500,000

by 2023."

MARKET RESEARCH FUTURE







ADDITIONAL TRENDS RELATING TO LIFEVANTAGE PRODUCTS

ANTI-AGING

Nrf2, NRF1, TrueScience Skin Care

2015: **\$140.3 bn**

2021: **\$216** bn

SKIN CARE

TrueScience

2015: **\$121 bn**

2021: **\$154** bn

NOOTROPICS (BRAIN HEALTH)

Axio, NRF1

2015: **\$2.3 bn**

2021: **\$11.6** bn

WEIGHT LOSS

PhyslQ

2015: **\$158 bn**

2021: **\$241** bn

HAIR CARE

HAIR CARE

2017: **\$89 bn**

2024: **\$110** bn





DIRECT SELLING CHANNEL

A LARGE GLOBAL SALES CHANNEL IDEALLY SUITED FOR OUR PRODUCTS

- Global sales of \$190 billion in 2017
- More than 117 million direct sellers worldwide
- Trend towards entrepreneurship
 - 18% of Boomers
 - 33% of Gen X
 - 63% of Millennials

INDUSTRY TRENDS




15

DIRECT SELLING IN THE U.S.


PEOPLE INVOLVED IN DIRECT SELLING


(in millions)



US RETAIL SALES

(in billions)





Source: Direct Selling Association

ROOM FOR GROWTH

REGIONAL SALES AND TOP 3 PRODUCT CATEGORIES.



North America: \$36.9 billion Europe: \$38.5 billion • Wellness: **32**% • Wellness: **34**% • Cosmetics & Personal Care: 17% Cosmetics & Personal Care: 26% • Household Goods & Durables: 14% Home Improvement: 12% South & Central America: \$27.1 billion Asia-Pacific: \$85.4 billion Cosmetics & Personal Care: 67% • Wellness: 50% Cosmetics & Personal Care: 23% • Wellness: 14% Clothing & Accessories: 6% Household Goods & Durables: 11%

Source: Direct Selling News, 2017 data

Current LifeVantage Market



GROWTH OPPORTUNITIES

GEOGRAPHICAL

Greater China expansion utilizing an e-commerce model Opened Taiwan June 2018 Opened Austria September 2018 Opened Spain March 2019 Opened Ireland May 2019

EXPANDING DISTRIBUTOR BASE

While most companies are scrambling for customers to talk about and recommend their products, we have over 70,000 created both organically and through our "Red Carpet" program

FOCUS ON DRIVING SUBSCRIPTION PLATFORM

80% of current revenue derived from subscriptions

NEW PRODUCTS

TOOLS AND TECHNOLOGIES

CROSS BORDER E-COMMERCE PROGRAM INTO MAINLAND CHINA

ENTERED MAINLAND CHINA THROUGH AN INNOVATIVE E-COMMERCE AND SOCIAL INFLUENCER MODEL

- Formally launched on February 1, 2018
- Business model is not multi-level marketing
- Utilizing third party social influencers in China
- Products already approved for e-commerce

EXPANDING DISTRIBUTOR BASE

Enhancing the demographics and skillset of our distributor base

RED CARPET PROGRAM

- Recently deployed an enhanced effort to attract new experienced leaders to LifeVantage through a program focused on creating relationships with developed leaders with access to our corporate leadership team, while providing activity based incentives as they build their business
- Incentivize experienced sales leaders to attract and retain accomplished salespeople to drive our business

- Focused on enhancing distributor base by attracting a second wave of leaders who are technology adept and social commerce savvy
- History of success with similar programs, which have demonstrated significant return on investment

NEW PRODUCT INTRODUCTIONS 2018-2019

VITALITY STACKS

Reconfigured product strategy from single products to a regimen that creates integrated product systems

Combining several of our powerful nutrigenomic products into a single solution that will become the basis of our bio-hacking protocol

Vitality Stack
Beauty Stack

Introduced Vitality Stack Packets, providing convenient single-day serving size for on-the-go customers

FLAGSHIP PRODUCTS TO KEY GROWTH MARKETS

Launched Protandims in Mexico, Thailand, and Australia

NEW PRODUCT LAUNCHES

FY2018 – Omega+, TruScience Hand Cream

FY2019 – TrueScience Hair Care System® in October 2018

FY2019 – PhysIQ System® Update in February 2019

truescience

Hair Care System

Launched on October 30, 2018

- Engineered with Nrf2 ingredients
- Backed by independent market research
- Scores very well on popular app
 Think Dirty targeting ingredient conscious consumers focused on on clean and safe personal care products

\$89 billion global industry, growing to \$110 billion by 2024¹





Launched on February 8, 2019


We do weight management differently – with less fad and more science to give you a better way to feel great.*

By working with your body's natural systems, PhysIQ balances your digestive system, supports your metabolism to burn fat, and provides protein and amino acids to help build lean muscle and keep you feeling full.*

Used as part of a healthy diet and exercise program, it can help you optimize your health in a way nature intended. It's a hard-working weight management system that helps you achieve your fitness goals.*

^{*} These statements have not been evaluated by the Food and Drug Administration.
These products are not intended to diagnose, treat, cure, or prevent any disease.





FINANCIAL OVERVIEW


MAY 2019





SALES HISTORY

LIFEVANTAGE



May 2015 New CEO

Began to implement growth initiatives

September 2016 Disruption

 Review of cross border sales resulted in policy and procedure adjustments that interrupted sales momentum

March 2017 Management Enhancements

Recruited experienced CFO and COO

Fiscal 2018 Initiatives


- Implemented key initiatives focused on increasing average order size, geographical expansion and distributor and customer acquisition
- Sequential and year-over-year sales growth accelerates

Continuing and Expanding Initiatives in Fiscal 2019



GLOBAL REACH

PERCENTAGE OF SALES BY AREA





LAUNCHED INITIATIVES

2019

- Continue geographical expansion
 - Building the Greater China region with the recent launch of Taiwan in June 2018
 - Opened Austria in September 2018, Spain in March 2019 and Ireland in May 2019
 - Announced intention to open Belgium later in fiscal 2019
- Further expand successful Red Carpet program to attract new and experienced direct sales leaders to LifeVantage
 - Utilize PaceSetter program to further build engagement and advancement
- Build upon the LifeVantage Digital technology platform with incremental functionality and enhancements
- Continue to develop new innovative products and stacks
 - Launched True Science Hair Care System at Global Convention in October
 - Relaunched PhyslQ Weight Management System at Elite Academy in February
- Strengthen current markets with further improvements to active member counts, retention and average order size
- Optimize the benefits, branding and publicity associated with LifeVantage's jersey front sponsorship of the Real Salt Lake
 Major League Soccer club
 - Leverage Auto-Assigned Customer Program
- Develop an IT Roadmap, evaluating core distributor and customer facing systems



AMERICAS MARKET

LIFEVANTAGE



73% OF SALES


- Launched Protandim Nrf2, Omega+, ProBio in Mexico
- Successful Leadership Events
 - Elite Academy in Charleston
 - Global Convention event in Salt Lake City
 - Elite Academy in Anaheim
 - Elite Academy in Denver
 - Canada Leadership Academy in Vancouver
 - Elite Academy in Orlando
 - Elite Academy in Indianapolis





ASIA PACIFIC AND EUROPE MARKETS

LIFEVANTAGE



27% OF SALES

- Product expansion into Australia, Thailand, EU and Taiwan
- Country Launches
 - Germany in September 2017
 - China in February 2018
 - Taiwan in June 2018
 - Austria in September 2018
 - Ireland in May 2019
- Successful Leadership Events
 - Elite Academy event in Japan
 - European Leadership Academy event in Netherlands





BUSINESS MODEL

LIFEVANTAGE

(as % of revenue)	FY 2016	FY 2017	FY 2018	Long-term Target
Gross Margin ¹	83.6%	83.2%	82.4%	84.0%
Commissions and Incentives	49.9%	48.5%	48.3%	48.0%
SG&A ²	26.3%	30.4%	29.0%	24.0%
Operating Margin ³	7.3%	4.2%	5.1%	12.0%
Adjusted EBITDA Margin ³	9.5%	6.6%	7.3%	14.5%

A reconciliation of non-GAAP items is included at the appendix of this presentation

¹ Non-GAAP adjustments to FY 2018 gross margin to exclude the benefit related to a change in estimate for the accrual of import duties. A full reconciliation of FY2018 adjusted earnings are included at the end of this presentation

Non-GAAP adjustments to FY 2016 to FY2018 SG&A to exclude expenses associated with the audit committee review, class action expenses, non-recurring legal expenses, reverse split fees, insurance reimbursement and recruiting, severance and management transition fees. A full reconciliation of FY2016 to FY2018 adjusted earnings are included at the end of this presentation

Non-GAAP adjustments to FY 2016 to FY2018 include the adjustments noted above. A full reconciliation of FY2016 to FY2018 adjusted earnings are included at the end of this presentation

INVESTMENT SUMMARY

(+)

Well positioned with on-trend scientific products in a growing, global sales channel

Continuous focus on product innovation and international market opportunities position us for growth

Highly efficient, subscription based business model with strong cash flow and high incremental margins



APPENDIX



RECENT OPERATING RESULTS COMPARISON

LIFEVANTAGE

LIFEVANTAGE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)	Most Recent Quarter		Prior Year Period		Year over Year Change	Previous Sequential Quarter		Sequential Change
(In thousands, except per share data)	Q3 of Fiscal 2019		Q3 of Fiscal 2018		%	Q2 of Fiscal 2019		%
Revenue, net	\$	56,012	\$	50,562	10.8%	\$	58,167	(3.7%)
Cost of sales	_	9,270	ē	8,921		_	9,794	
Gross profit		46,742		41,641	12.2%		48,373	(3.4%)
Commissions and incentives		27,205		24,320			28,176	
Selling, general and administrative	<u></u>	17,296	·	15,023			1 9,61 6	
Total operating expenses	<u></u>	44,501	81	39,343			47,792	
Operating income		2,241		2,298	(2.5%)		581	285.7%
Interest expense		(72)		(92)			(1 00)	
Other income (expense), net	_	(11)		27			(72)	
Total other income (expense)	00	(83)	S	(65)			(172)	
Income before income taxes		2,158		2,233			409	
Income tax (expense) benefit	8	(376)	-	(598)			420	
Net income	2	1,782		1,635	9.0%		829	115.0%
EPS (Net income per share, basic)	\$	0.13	\$	0.12	8.3%	\$	0.06	116.7%
EPS (Net income per share, diluted)	\$	0.12	\$	0.12	0.0%	\$	0.06	1 00.0%
Weighted average shares, basic		14,165		14,006			13,944	
Weighted average shares, diluted		15,286		14,178			14,963	
Non-GAAP Items								
Adjusted EBITDA*		4,028		3,410	18.1%		3,270	23.2%
Adjusted Net Income*		1,969		1,770	11.2%		1,908	3.2%
Adjusted EPS (Net income per share, diluted)*	\$	0.13	\$	0.12	8.3%	\$	0.13	0.0%

^{*} A reconciliation of non-GAAP items, including Adjusted EBITDA, Adjusted Net Income and Adjusted Earnings per Diluted Share, is included at the appendix of this presentation



HISTORICAL INCOME STATEMENTS

LIFEVANTAGE

LIFEVANTAGE CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(Unaudited)	Fiscal Year ended June 30,							Nine Months ended March 31,				
(In thousands, except per share data)		2016		2017		2018). .	2018		2019		
Revenue, net	\$	206,540	\$	199,489	\$	203,204	\$	149,171	\$	169,788		
Cost of sales	·-	33,932	<u> </u>	33,456		34,848		26,778	99	28,263		
Gross profit		172,608		166,033		168,356		122,393		141,525		
Commissions and incentives		103,120		96,662		98,193		71,124		83,166		
Selling, general and administrative		56,074		64,922		59,840		45, 246		54,213		
Total operating expenses		159,194	8	161,584	10	158,033		116,370	\$ -	137,379		
Operating income		13,414	22	4,449	EN -	10,323		6,023	9.	4,146		
Interest expense		(3,321)		(570)		(456)		(357)		(282)		
Other expense, net	e	(1,409)	82	(969)	8	(31 9)	6	(120)	(6	(132)		
Total other expense		(4,730)		(1,539)	40	(775)	*	(477)	9.5	(41 4)		
Income before income taxes		8,684		2,910		9,548		5,546		3,732		
Income tax expense	2	(2,578)		(1,302)	1	(3,787)		(2,777)		(21 0)		
Net income		6,106		1,608	9	5,761		2,769		3,522		
EPS (Net income per share, basic)	\$	0.44	\$	0.12	\$	0.41	\$	0.20	\$	0.25		
EPS (Net income per share, diluted)	\$	0.42	\$	0.11	\$	0.41	\$	0.20	\$	0.24		
Weighted average shares, basic		13,730		13,881		13,992		13,975		14,027		
Weighted average shares, diluted		14,531		14,118		14,136		14,136		14,978		
Non-GAAP Items												
Adjusted EBITDA*		19,650		13,087		14,910		9,734		10,558		
		9,235		3,932				4,387				
Adjusted EPS (Net income per share, diluted)*	\$	0.64	\$	0.27	\$	0.51	\$	0.31	\$	0.33		
Total other expense Income before income taxes Income tax expense Net income EPS (Net income per share, basic) EPS (Net income per share, diluted) Weighted average shares, basic Weighted average shares, diluted Non-GAAP Items Adjusted EBITDA* Adjusted Net Income*		(4,730) 8,684 (2,578) 6,106 0.44 0.42 13,730 14,531 19,650 9,235		(1,539) 2,910 (1,302) 1,608 0.12 0.11 13,881 14,118 13,087 3,932		(775) 9,548 (3,787) 5,761 0.41 0.41 13,992 14,136 14,910 7,194		(477) 5,546 (2,777) 2,769 0.20 0.20 13,975 14,136 9,734 4,387		(41 4) 3,732 (21 0) 3,522 0.25 0.24 14,027 14,978 10,558 4,915		

^{*} A reconciliation of non-GAAP items, including Adjusted EBITDA, Adjusted Net Income and Adjusted Earnings per Diluted Share, is included at the appendix of this presentation



HISTORICAL BALANCE SHEET AND CASH FLOWS

LIFEVANTAGE

LIFEVANTAGE CORPORATION AND SUBSIDIARIES

SUMMARIZED BALANCE SHEET AND CASH FLOW METRICS

	As of June 30,						As of March 31,			
(Unaudited, in thousands, except per share data)		2016		2017	-	2018		2018		2019
Cash and Cash Equivalents	\$	7,883	\$	11,458	\$	16,652	\$	13,952	\$	15,913
Current Portion of Long-term Debt Long-term Debt, Net of Discount		2,000 7,409		2,000 5,440	7	2,000 3,412		2,000 3,965		1,939
Total Debt Net Cash (Cash and equivalents less total Debt) Net Cash per share, diluted	\$	9,409 (1,526) (0.11)	\$	7,440 4,018 0.28	\$	5,412 11,240 0.80	\$	5,965 7,987 0.57	\$	1,939 13,974 0.93
Total Assets Total Stockholders' Equity		50,855 10,649		45,249 14,527		51,142 21,947		50,929 19,302		54,105 24,746
Book Value per share, diluted	\$	0.73	\$	1.03	\$	1.55	\$	1.37	\$	1.65
	Fiscal Year ended June 30,				,	Nine Months ended			led March 31,	
(Unaudited, in thousands, except per share data)		2016		2017		2018		2018		2019
Net Cash Provided by Operating Activities Capital Expenditures	\$	6,036 562	\$	6,597 1,055	\$	13,256 4,649	\$	7,785 3,367	\$	10,805 1,689
Free Cash Flow Free Cash Flow per share, diluted	\$	5,474 0.38	\$	5,542 0.39	\$	8,607 0.61	\$	4,418 0.31	\$	9,116 0.61

^{*} A reconciliation of non-GAAP items, including Adjusted EBITDA, Adjusted Net Income and Adjusted Earnings per Diluted Share, is included at the appendix of this presentation



NON-GAAP RECONCILIATIONS

LIFEVANTAGE

LIFEVANTAGE CORPORATION AND SUBSIDIARIES

Adjusted Net Income

(Unaudited, in thousands, except per share data)	Fiscal Year ended June 30,		Three Mont March		Nine Months ended March 31,		
	2016	2017	2018	2018	2019	2018	2019
GAAP net income	\$6,106	\$1,608	\$5,761	\$1,635	\$1,782	\$2,769	\$3,522
Adjustments:							
Recall related expenses		_	a -a	_	_	_	_
Executive team recruiting and transition expenses	928	744	207	_	_	207	_
Audit committee independent review expenses	_	2,742	_	_	_	_	_
Class-action lawsuit expenses	_	170	659	125	159	341	527
Executive team severance expenses, net	632	39	374	60	_	60	(79)
Reverse split fees	159	_	_	_	_	_	_
Write-off of deferred debt offering costs	1,544	_	_	_	_	_	_
Write-off of intangible assets	· —	350		_	_	_	_
Write-off of capitalized software development costs	1,186	1	_	_	_	_	_
Other nonrecurring legal and accounting expenses	_	160	51	_	67	51	472
Insurance reimbursement	×	· —	(425)	_	<u></u>	_	
Change in estimate of accrued import liabilities	_	_	(863)	_	_	_	_
Tax impact of adjustments	(1,320)	(1,881)	(42)	(50)	(39)	(207)	473
Tax expense impact of revaluation of deferred tax assets	· · · · · · · · · · · · · · · · · · ·	20 20 20 20 20 20 20 20 20 20 20 20 20 2	1,472		-	1,166	_
Total adjustments, net of tax	3,129	2,324	1,433	135	187	1,618	1,393
Non-GAAP net income:	9,235	3,932	7,194	1,770	1,969	4,387	4,915
Diluted earnings per share, as reported	0.42	0.11	0.41	0.12	0.12	0.20	0.24
Total adjustments, net of tax	0.22	0.16	0.10	0.01	0.01	0.11	0.09
Diluted earnings per share, as adjusted	0.64	0.27	0.51	0.12	0.13	0.31	0.33



NON-GAAP RECONCILIATIONS

LIFEVANTAGE

LIFEVANTAGE CORPORATION AND SUBSIDIARIES

EBITDA and Adjusted EBITDA

(Unaudited, in thousands		Fiscal Year		Three Mont March		Nine Months ended March 31,		
	2016	2017	2018	2018	2019	2018	2019	
GAAP net income	\$6,106	\$1,608	\$5,761	\$1,635	\$1,782	\$2,769	\$3,522	
Interest expense	3,321	570	456	92	72	357	282	
Provision for income taxes	2,578	1,302	3,787	598	376	2,777	21 0	
Depreciation and amortization	1,895	1,643	1,325	270	478	942	1,356	
Non-GAAP EBITDA:	13,900	5,123	11,329	2,595	2,708	6,845	5,370	
Adjustments:								
Stock compensation expense	2,621	2,647	3,196	657	1,083	2,110	4,136	
Other (income) expense, net	1,409	969	319	(27)	11	120	132	
Other adjustments	1,720	4,348	66	185	226	659	920	
Total adjustments	5,750	7,964	3,581	81 5	1,320	2,889	5,188	
Non-GAAP Adjusted EBITDA	19,650	13,087	14,910	3,410	4,028	9,734	10,558	